<DOC>
	<DOCNO>NCT02357277</DOCNO>
	<brief_summary>There 10 million individual asthma use inhaled glucocorticoid ( IGCs ) United States . While oral GCs recognize destructive skeletal effect , far less known effect IGCs . This gap knowledge critical importance , prevalence , chronic nature long duration IGC use , also several study find patient use IGCs increase risk fracture . Fracture risk great postmenopausal ( PM ) woman , IGCs may augment negative effect estrogen loss aging . The investigator hypothesize initiation IGCs IGC naïve PM woman lead decreased bone formation uncouple bone turnover , potential mechanism effect IGCs skeleton . To test hypothesis , investigator perform randomize , control 4 week study acute effect commonly use dos budesonide ( 360 720 mcg ) bone turnover circulate osteoblast precursor 60 treatment naïve , non-asthmatic , PM woman . These study high clinical significance currently guideline regard screening , prevention treatment osteoporosis patient use IGCs , IGC use take account calculate fracture risk PM woman , group high risk fracture . High quality evidence low volumetric bone mineral density ( BMD ) abnormal bone quality PM woman use IGCs potential change clinical practice support specific intervention prevent bone loss fracture .</brief_summary>
	<brief_title>The Effects Inhaled Glucocorticoids Postmenopausal Skeleton</brief_title>
	<detailed_description>The investigator study acute biochemical hormonal response 4 week commonly prescribe moderate high dos budesonide one widely prescribe IGCs , preferred drug Medicare Medicaid . Sixty treatment naïve PM non-asthmatic woman randomize one 3 group ( 20/group ) : placebo , budesonide 360 720 mcg/day . IGCs self-administered 2 puff twice daily . Budesonide provide Pulmicort flexhaler . At baseline visit , subject teach proper technique self-administration inhaled medication , include mouth rinse dose . Since dry powder formulation use , spacer device require . Women assess baseline , 1,2 , 4 week . This time period schedule choose ensure adequate time IGCs reach peak level , assess bone metabolic response . Given 4-6 hr half-life budesonide , steady state pharmacokinetics reach one week . The investigator monitor medication adherence use inhaler 's device counter . Visits conduct Metabolic Bone Diseases Unit . To measure systemic absorption , serum steroid level directly measured.To assess effect IGC dose hypothalamic-pituitary-adrenal ( HPA ) axis , morning ( AM ) cortisol measure visit urinary free cortisol baseline 4 week .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Glucocorticoids</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Age ≥ 60 year least &gt; 5 year postmenopause ( define 1 year without menstrual period ) No asthma history GC use , either oral inhale Use oral GCs &gt; 4 week per year past 3 year History smoking , rule overlap chronic obstructive pulmonary disease ( COPD ) Other metabolic bone disease ( e.g . hyperparathyroidism , Paget 's disease , osteogenesis imperfecta ) Gastrointestinal Disease ( malabsorption , celiac disease , inflammatory bowel disease ) Endocrinopathies ( i.e . untreated thyroid disease , Cushing 's syndrome , prolactinoma , ) Current use osteoporosis medication ( hormone replacement therapy ( HRT ) , raloxifene , bisphosphonates , denosumab ) Current past use teriparatide estimate glomerular filtration rate ( eGFR ) &lt; 45 ml/min calculate MDRD112 accommodate mild decline renal function due age History malignancy , except cure skin cancer Diabetes , ( HbA1c &gt; 6 ) disease also associate decrease bone formation Osteoporosis Dualenergy Xray Absorptiometry ( DXA ) site asymptomatic vertebral fracture</criteria>
	<gender>Female</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Osteoporosis</keyword>
	<keyword>Glucocorticoids</keyword>
	<keyword>Postmenopausal</keyword>
</DOC>